4,6-Difluoroindole | CAS:199526-97-1

We serve 4,6-Difluoroindole CAS:199526-97-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4,6-Difluoroindole

Chemical Name:4,6-Difluoroindole
CAS.NO:199526-97-1
Synonyms:4,6-Difluoroindole
4,6-difluoro-1H-indole
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 253.2±20.0 °C at 760 mmHg
Molecular Formula C8H5F2N
Molecular Weight 153.129
Flash Point 106.9±21.8 °C
Vapour Pressure 0.0±0.5 mmHg at 25°C
Index of Refraction 1.616
 
Specification:
Appearance:Light yellow to yellow liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4,6-Difluoroindole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,6-difluoro-1H-indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,6-difluoro-1H-indole Use and application,4,6-difluoro-1H-indole technical grade,usp/ep/jp grade.


Related News: Countries across Asia, Europe, Australia and North America have also had confirmed cases, including the UK.3-Methoxyacrylic Acid Methyl Ester manufacturer Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.(2E)-2-(1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-ylidene)acetonitrile supplier Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.benzyl (S)-2,5-dioxooxazolidine-4-acetate vendor Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.